abatacept sold brand name orencia medication used treat autoimmune diseases like rheumatoid arthritis interfering immune activity modified abatacept fusion protein composed fc region immunoglobulin fused extracellular domain order cell activated produce immune response antigenpresenting cell must present two signals cell one signals major histocompatibility complex mhc combined antigen signal molecule also known abatacept binds molecule prevents second signal without second signal cell cant activated abatacept developed bristolmyers squibb licensed united states treatment rheumatoid arthritis case inadequate response antitnfÎ± therapy abatacept received approval fda abatacept used treat adults moderate severe rheumatoid arthritis ra secondline agent firstline agent people whose ra severe rapidly progressing also used treat psoriatic arthritis juvenile idiopathic abatacept tested pregnant women known secreted breast milk causes birth defects rodents given high doses transmitted rodent breast abatacept likely interfere vaccine given people taking used combination anakinra tnf abatacept anakinra tnf antagonists suppress immune system using combination may significantly increase risk severe people experienced serious infections due abatacepts suppression immune system infections fatal people copd likely get lung infections often usual people anaphylactic reactions drug abatacept may cause otherwise slowgrowing cancers proliferate spread due suppression immune common adverse effects occurring people include upper respiratory tract infections common adverse effects occurring people include lower respiratory tract infections urinary tract infections herpes infections pneumonia flu cough high blood pressure stomach pain diarrhea nausea vomiting upset stomach mouth sores elevated transaminases rashes fatigue weakness local injection site reactions systemic injection abatacept fusion protein composed extracellular domain hinge domains abatacept soluble analog prevents antigenpresenting cells apcs delivering costimulatory signal prevents cells fully activated even downregulates simple signaling without costimulation allows cell recognize primary signal self rampup responses future responses well order cells activated attack antigen antigen must presented cell apc activation requires two signals one called costimulatory signal signal signal apc must bind antigen major histocompatibility complex mhc molecule bring complex surface present cell receptor surface cell signal apc must present protein cell surface protein surface cell two signals activate cell without signal cell activated become anergic abatacept consists fusion protein extracellular domain human binds protein apc prevents delivering costimulatory signal abatacept basis secondgeneration belatacept approved fda drugs differ amino acids organ transplantation belatacept intended provide extended graft survival limiting toxicity generated standard immunesuppressing regimens calcineurin inhibitors example cyclosporincitation needed httpsenwikipediaorgwikiabatacept